Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

- Memorial Sloan-Kettering Cancer Center Investigators to Assess BSI-201

Therapy in BRCA-Negative Ovarian Cancer Patients -

BRISBANE, Calif., May 8 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on-going trials in breast and brain cancer.

The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.

"We believe BSI-201 holds great promise as a targeted therapy in this difficult-to-treat type of ovarian cancer," said Carol Aghajanian, M.D., co- principal investigator and chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center. "BRCA-negative patients are at higher risk of breast and ovarian cancer because BRCA plays a key role in repairing DNA errors that lead to tumor formation."

Ovarian cancer strikes more than 21,000 women a year in the United States and is one of the most common causes of cancer death in women, killing more than 15,000 annually in the United States. Patients with the hereditable BRCA- negative form of the disease account for about 15 percent of the patient population. Women with defective BRCA genes are also at considerably higher risk of breast cancer.

"We have identified a number of important types of cancer where PARP plays a crucial role in tumor growth, and we believe that BRCA-negative ovarian cancer represents another excellent target for BSI-201," said Barry Sherman, M.D., BiPar's Executive Vice President of Development. "We will soon have patients enrolled in four separ
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015   Rock Creek Pharmaceuticals, Inc., ... focused on the treatment of chronic inflammatory disorders, announced ... to the Company,s Board of Directors with the recent ... a new director. Michael Mullan ... Pharmaceuticals, said, "Dr. Samuel,s experience in advancing biotechnology products ...
(Date:4/21/2015)... , April 21, 2015  Direct contracting continues ... as aptitude marks its second anniversary.  With over ... platform, single hospital entities, large integrated delivery systems ... that cover medical surgical items, clinical preference products ... cost effective - complementary contracting strategy, aptitude seeks ...
(Date:4/21/2015)... , April 21, 2015  Game-changing ... the latest being the European Commission,s ruling on ... global leader and champion of pharmaceutical supply ... of meeting these mandates and offers several tools ... many countries. From an upcoming webinar in May ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 2Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 3Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 4Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 5Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 6Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 7Healthcare's first direct contracting market celebrates second anniversary 2Frequentz Gives the Global Pharmaceutical Supply Chain a Shoulder to Lean On as They Face Expanding Serialization Requirements 2Frequentz Gives the Global Pharmaceutical Supply Chain a Shoulder to Lean On as They Face Expanding Serialization Requirements 3
(Date:4/21/2015)... (PRWEB) April 21, 2015 The joint ... today it is opening its first freestanding emergency room ... Chandler, Arizona and will be licensed under Dignity Health ... Dignity Health and Adeptus Health joint venture. , Tim ... and Mercy Gilbert Medical Centers said the new facility ...
(Date:4/21/2015)... NJ & New York, NY (PRWEB) April 21, ... leading global provider of advanced delivery technologies and ... products, today announced the launch of ADVASEPT™ Lock, ... safe and efficient delivery of injectable medications. Easily ... combining a safe, convenient and functional container closure ...
(Date:4/21/2015)... Carinsurancehints.com has released a new blog ... impact on auto insurance prices . , ... prices. Clients should review their insurance options before deciding ... under several forms. Some of the popular policies provide ... compare online rates and find the best prices in ...
(Date:4/21/2015)... PA (PRWEB) April 21, 2015 This ... & Related Skin Types, Inc.® (FIRST) will publish a ... The campaign will run throughout the month of May ... It Matters to Someone." The positioning was chosen ... this rare skin disorder and to help support our ...
(Date:4/21/2015)... Carinsuranceshoppingsource.com has released a new blog ... insurance plans . , Comprehensive auto insurance is ... situations. The coverage limit can also be high and ... protect a car against fire damage, vandalism, theft and ... no longer difficult and it can help drivers find ...
Breaking Medicine News(10 mins):Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2Health News:Comprehensive Auto Insurance Is An Important But Complex Policy 2
... Kiadis Pharma,announced today that its lead product ATIR ... Food and Drug Administration (FDA) as a therapy ... Disease (GvHD),following allogeneic bone marrow transplantation. ATIR is ... enter clinical phase III,studies in 2008. "This ...
... to treat high blood pressure and enlargement of ... caused by post-traumatic stress disorder, Alzheimer,s disease, depression ... antipsychotic medication, appears to block the increase of ... Science University and Portland Veterans Affairs Medical Center ...
... Scientists at Cold Spring Harbor Laboratory (CSHL) have developed a ... genome that is more powerful and more economical than methods ... to be a boon to many kinds of research, including ... genes implicated in major diseases such as cancer and schizophrenia. ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported financial ... the quarter ended September 30, 2007, the Company reported a ... to a net loss of,$62.7 million, or $1.23 per share, ... per share, for the prior quarter ended June 30, 2007. ...
... and 6 ... other cities, RALEIGH, N.C., ... on the impact of new CPR techniques, the,results of which support the ... the study authors in a,presentation at the AHA,s Scientific Sessions on November ...
... Concise reporting would ensure validity of patient safety findings, group ... to be used as hospital safety rating tools have been ... the guidelines could help do away with misleading safety comparisons ... reporting patient safety data on their Web sites. While this ...
Cached Medicine News:Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 3Health News:Blood pressure drug curbs brain damage from PTSD 2Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 2Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 3Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 4Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 5Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 6Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 7Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 8Health News:Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device 2Health News:Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device 3
For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
... tips. Each box contains 1000 tips (5 bags ... tips (4 bags of 50 tips). Also available ... per pack. Bulk Packs are sealed with a ... quick access to Gilsons Diamond Tips. Bulk Packs ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels - Ideal for use with CastAway System...
Medicine Products: